Raymond James Downgrades Avidity Biosciences to Market Perform

Benzinga Newsdesk Oct 27, 2025 1 year ago

NewsDowngradesAnalyst Ratings

Raymond James analyst Martin Auster downgrades Avidity Biosciences (NASDAQ:RNA) from Strong Buy to Market Perform.